Prescription Drug Affordability Boards (PDABs) and Upper Payment Limits (UPLs) Impact on Patients, Drug Pricing, and Innovation

This HealthHIV Advocacy paper explores the function of Prescription Drug Affordability Boards (PDABs) in managing prescription drug costs, considering perspectives of patients, providers, and payers to ensure equitable access to vital medications while controlling healthcare expenses. 

Concerns have risen regarding the potential negative impacts of PDABs on patient access to vital medications, highlighted by recent data showing thousands of patients in various states who might be affected, particularly those with conditions such as Cancer, HIV, and Hepatitis C.